Last reviewed · How we verify
A Phase I Study of Subutinib Maleate Capsules on Toleration and Pharmacokinetics
1. purpose: to explore the maximum tolerated dose, dose-limiting toxicity of oral Subutinib Maleate capsules and rational dosage regimen for phase Ⅱ study 2. Experimental Design： A phase Ⅰ study of single-center 3. Test drug: Subutinib Maleate capsules 4. Sample size≥20
Details
| Lead sponsor | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | UNKNOWN |
| Enrolment | 20 |
| Start date | 2013-03 |
| Completion | 2014-09 |
Conditions
- Solid Tumor
Interventions
- Subutinib Maleate capsules
Primary outcomes
- Dose-limiting toxicity， maximum tolerated dose. — 2 months
Countries
China